Search
Search
Editorially independent content, supported with advertising
11.19.20
In episode 2 of the NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data,” Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution? This editorially independent podcast is supported with advertising.
03.24.22
Art of Drug Choice: Treating New Wet AMD PatientsArshad M. Khanani, MD, MA; Lejla Vajzovic, MD, and Joseph M. Coney, MD
03.17.22
Art of Drug Choice: Who Is Best Suited for Extended-duration Therapy?Arshad M. Khanani, MD, MA; Lejla Vajzovic, MD; and Joseph M. Coney, MD
03.03.22
Art of Drug Choice: The Latest Advances in Wet AMD TherapyArshad M. Khanani, MD, MA; Lejla Vajzovic, MD, and Joseph M. Coney, MD
09.10.21
The Art of Drug Choice: International Panel in Wet AMD: Safety DataArshad M. Khanani, MD; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; Peter Kertes, MD, FRCSC
09.01.21
The Art of Drug Choice: International Panel in Wet AMD: The PipelineArshad M. Khanani, MD; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; Peter Kertes, MD, FRCSC
08.20.21
The Art of Drug Choice: International Panel in Wet AMD: Phase 3 and Real-World Data to WatchArshad Khanani, MD, MA; Justus Garweg, MD; Seenu Hariprasad, MD; Peter Kertes, MD, FRCSC
08.06.21
The Art of Drug Choice: International Panel in Wet AMD: When and Why Switching Therapy Makes SenseArshad M. Khanani, MD, MA; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; and Peter Kertes, MD, FRCSC
11.19.20
The Art of Drug Choice: Safety in Wet AMDArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
11.19.20
The Art of Drug Choice: Wet AMD PipelineArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
11.19.20
The Art of Drug Choice: Phase 3 Trials in Wet AMDArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
